Oral trofosfamide: An active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis

Onkologie

Volumn 25, Issue 6, 2002, Pages 541-546

  Reichardt, P ^a   Pink, D ^b   Tilgner, J ^b   Kretzschmar, A ^b   Thuss Patience, P C ^b   Dorken B ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

Maintenance therapy; Progression free survival; Sarcomas; Toxicity; Trofosfamide

Indexed keywords

TROFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY; DRUG EFFICACY; DRUG SCREENING; FEMALE; FOLLOW UP; HEMATOLOGY; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHROTOXICITY; OSTEOSARCOMA; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0036986318     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068625     Document Type: Article

References (25)

1. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
2. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL: An Intergroup phase III randomized study of doxorubicin and dacarbacine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
3. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993;11:15-21.
4. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545.
5. Reichardt P, Tilgner J, Hohenberger P, Dörken B: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998;16:1438-1443.
6. Blay JY, Van Glabbeke M, Nielsen OS, van Oosterom AT, Tursz T, Oosterhuis JW, Verweij J: Five-year survivors in patients with advanced soft tissue sarcoma treated with doxorubicin: A study on 1742 patients. Proc Am Soc Clin Oncol 1998;17:512a (abstr).
7. Bielack S, Kempf-Bielack B, Schwenzer D, Birkfellner T, Delling G, Ewerbeck V, Exner GU, Fuchs N, Gobel U, Graf N, Heise U, Helmke K, von Hochstetter AR, Jurgens H, Maas R, Munchow N, Salzer-Kuntschik M, Treuner J, Veltmann U, Werner M, Winkelmann W, Zoubek A, Kotz R: Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients. Klin Pádiatr 1999;4:260-270.
8. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, Amann G, Dockhorn-Dworniczak B, Harms D, Muller-Weihrich S, Welte K, Kornhuber B, Janka-Schaub G, Gobel U, Treuner J, Voute PA, Zoubek A, Gadner H, Jurgens H: Localized Ewing tumor of bone: Final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001;6:1818-1829.
9. Antman KH, Ryan L, Elias A, Sherman D, Grier HE: Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-131.
10. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J: High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13:1600-1608.
11. Reichardt P, Tilgner J, Sachs U, Pecher G, Dörken B: High-dose ifosfamide in heavily pretreated patients with bone and soft tissue sarcoma. Ann Hematol 1996;73(suppl 2):A100 (abstr).
12. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS: High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - dose response and schedule dependence. J Clin Oncol 1997;15:2378-2384.
13. Nielsen OS, Judson I, van Hoesel Q, le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancarova L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW, Verweij J: Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicenter phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2000;36:61-67.
14. Boos J, Küpker F, Blaschke G, Jürgens H: Trofosfamide metabolism in different species - ifosfamide is the predominat metabolite. Cancer Chemother Pharmacol 1993;33:71-76.
15. Wagner A, Hempel G, Boos J: Trosofamide: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. Anticancer Drugs 1997;8:419-431.
16. Mross K, Rüther A, Gierlich T, Unger C: Tumor growth control by oral trofosfamide in patients with metastatic breast cancer. Onkologie 1998;21:52-56.
17. Wiedemann GJ, Zschaber R, Hegewisch-Becker S, Reichardt P, Weber K, Uthgenannt D, Löwenstrom O, Jäger E, Freund M, Seeger R, Feller AC, Merz H, Hartlapp JH, Wagner T, Illiger HJ: Two oral Trofosfamide schedules in elderly patients with refractory Non-Hodgkin's lymphoma. Onkologie 1999;22:134-138.
18. Horvath V, Bakhshande A, Hartlapp JH, Hegewisch-Becker S, Feyerabend T, Fischer v Weikersthal L, Illiger HJ, Jäger E, Peters SO, Reichardt P, Uthgenannt D, Weber D, Wagner T, Wiedemann GJ, Zschaber R: Oral trofosfamide in elderly and/or heavily pretreated patients with metastatic lung cancer. Onkologie 2000;23:341-344.
19. Blomquist C, Wiklund T, Pajunen M, Virolainen M, Elomaa I: Oral trofosfamide: An active drug in the treatment of soft-tissue sarcoma. Cancer Chemother Pharmacol 1995;36:263-265.
20. Kollmanusberger C, Brugger W, Hartmann JT, Maurer F, Bohm P, Kanz L, Bokemeyer C: Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999;10:453-456.
21. Demetri GD, Manola J, Harmon D, Maki RG, Seiden MV, Supko JG, Ryan DP, Puchlaski TA, Goss G, Merriam P, Waxman A, Slater S, Potter A, Quigley MT, Lopez T, Sancho MA, Guzman C, Jimeno J, Garcia-Carbonero R: Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas: Final results of phase II and pharmacokinetic studies in the U.S.A. Proc Am Soc Clin Oncol 2001;20:352a (abstr).
22. Le Cesne A, Blay JY, Judson I, van Oosterom AT, Verweij J, Radford J, Lorigan P, Rodenhuis S, Donato Di, Paola E, Van Glabbeke M, Jimeno J, Nielsen O: ET-743 is an active drug in adult soft-tissue sarcoma: a STBSG-EORTC phase ii trial. Proc Am Soc Clin Oncol 2001;20:353a (abstr).
23. Sculier JP, Berghmans T Castaigne C, Luce S, Sotiriou C, Vermylen P, Paesmans M: Maintenance chemotherapy for small cell lung cancer: A critical review of the literature. Lung cancer 1998;19:141-151.
24. Mansi JL, Fisher C, Wiltshaw E, MacMillan S, King M, Stuart-Harris R: A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol 1988;24:1439-1443.
25. Browder T, Butterfield CE, Kräling BM,Shi B, Marshall B, O'Reilly MS, Folkman J: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-1886.